|
A Controlled Prospective Study of Transfusion-Associated Hepatitis Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on A Controlled Prospective Study of Transfusion-Associated Hepatitis conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Controlled Prospective Study of Transfusion-Associated Hepatitis Clinical research trials and A Controlled Prospective Study of Transfusion-Associated Hepatitis healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including A Controlled Prospective Study of Transfusion-Associated Hepatitis. A Controlled Prospective Study of Transfusion-Associated Hepatitis Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a A Controlled Prospective Study of Transfusion-Associated Hepatitis clinical trial. Test subjects oftentimes recieve the best healthcare possible for their A Controlled Prospective Study of Transfusion-Associated Hepatitis condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Controlled Prospective Study of Transfusion-Associated Hepatitis  A Controlled Prospective Study of Transfusion-Associated Hepatitis
A Controlled Prospective Study of Transfusion-Associated Hepatitis
For Condition: Hepatitis
Status: Completed
Sponsor(s): Warren G Magnuson Clinical Center (CC) ,
Synopsis: This protocol represents a continuation of a series of prospective studies to define the incidence and etiology of transfusion-associated hepatitis (TAH) and to examine the impact on TAH of various modifications in the selection of blood donors. The primary goal of the study will be to determine TAH incidence after the institution of a variety of interventive measures to exclude hepatitis and AIDS virus carriers: including surrogate assays (ALT, anti-HBc), a specific assay for the hepatitis C virus (HCV), a specific assay for the human immunodeficiency virus (HIV) and intensified donor questioning for high-risk behavior patterns. There is high probability that the exclusion of donors at high risk for AIDS transmission will also exclude donors at high risk for hepatitis transmission. Incidence data obtained in the study will be enhanced by the simultaneous follow-up of a control population undergoing identical surgical procedures, but receiving no blood or only autologous blood. This control population, made possible by the recent dramatic increase in the amount of autologous blood utilized, will allow for a clear distinction between transfusion-associated hepatitis and that due to nosocomial transmission or other background causes of hepatocellular inflammation in cardiac surgery patients.
Details: This protocol represents a continuation of a series of prospective studies to define the incidence and etiology of transfusion-associated hepatitis (TAH) and to examine the impact on TAH of various modifications in the selection of blood donors. The primary goal of the study will be to determine TAH incidence after the institution of a variety of interventive measures to exclude hepatitis and AIDS virus carriers: including surrogate assays (ALT, anti-HBc), a specific assay for the hepatitis C virus (HCV), a specific assay for the human immunodeficiency virus (HIV) and intensified donor questioning for high-risk behavior patterns. There is high probability that the exclusion of donors at high risk for AIDS transmission will also exclude donors at high risk for hepatitis transmission. Incidence data obtained in the study will be enhanced by the simultaneous follow-up of a control population undergoing identical surgical procedures, but receiving no blood or only autologous blood. This control population, made possible by the recent dramatic increase in the amount of autologous blood utilized, will allow for a clear distinction between transfusion-associated hepatitis and that due to nosocomial transmission or other background causes of hepatocellular inflammation in cardiac surgery patients.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Consecutive patients undergoing open-heart surgery at Georgetown University and Fairfax Hospital will be admitted to the study if: They are 18 years of age or older; They provide informed consent; They reside in the United States and will be available for at least six months of follow up. Patients with known hepatitis C or hepatitis B virus carriers with or without evidence of chronic hepatitis will be excluded. Persons with a history of prior hepatitis will not be excluded, but will be analyzed as a separate cohort. Patients with close exposure (household or sexual contact) to hepatitis in the preceding six months will be excluded. Patients with elevated pre-operative alanine aminotransferase (ALT) will be excluded. An aspartate aminotransferase (AST) of between 45 and 75 IU per L will not serve as cause for exclusion if the corresponding ALT is normal on at least two occasions. A preoperative AST greater than 75 IU/L will serve to exclude patients from study independent of the ALT. Patients with blood transfusion in the six months preceding surgery will be excluded. Patients will also be retrospectively excluded if they receive blood more than one month after surgery. The six month followup period will be timed from the date of the last transfusion. Patients with alcoholism or other known liver or active biliary tract disease at the time of entrance into the study will be excluded. Patients with inadequate veins from which to obtain required samples will be excluded.
Total Enrollment: 2000
Location and Contact Information:
Warren G. Magnuson Clinical Center (CC)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 810110; 81-CC-0110
Study Start Date: July 6, 1981
Record last reviewed: July 26, 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004848
Other Hepatitis Studies:
1. Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
2. A Controlled Prospective Study of Transfusion-Associated Hepatitis
3. Hepatitis C: Grading and Staging by MR
4. Treating Nonalcoholic Steatohepatitis (NASH) with Metformin
5. Telbivudine versus Lamivudine in Adults with Decompensated Chronic Hepatitis B and Evidence of Cirrhosis
Related Studies:
Other Hepatitis Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
A Controlled Prospective Study of Transfusion-Associated Hepatitis
|
|
|
|
|
|
|
|
